ClinicalTrials.Veeva

Menu

An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

University of Wisconsin (UW) logo

University of Wisconsin (UW)

Status

Enrolling

Conditions

NASH
NAFLD

Treatments

Device: Magnetic Resonance Imaging (MRI)
Device: Ultrasound (US)

Study type

Observational

Funder types

Other

Identifiers

NCT06354491
2023-1494
A534800 (Other Identifier)
Protocol Version 7/9/24 (Other Identifier)

Details and patient eligibility

About

This study will validate recently developed Magnetic Resonance Imaging (MRI) and Ultrasound (US) based methods for liver fat quantification in children with obesity and healthy range of body mass index (BMI).

Full description

The severity of the obesity epidemic in the U.S., particularly in Wisconsin, is alarming, with overall overweight or obesity rates of 35% in children. [Fryar 2020,] Obesity is a major risk factor for several comorbidities, one of the most common being non-alcoholic fatty liver disease (NAFLD, also denoted steatotic liver disease). The inflammatory state known as non-alcoholic steatohepatitis (NASH) may lead to fibrosis and, if left untreated, can lead to cirrhosis, liver failure, and cancer. For these reasons, there is enormous interest in effective interventions for weight loss and reversing NAFLD. A central challenge in the development of new interventions is the need for accurate and precise biomarkers to evaluate hepatic steatosis in children.

This pilot study focuses on demonstrating the feasibility of MRI and US based liver fat quantification in children and addresses technical challenges that may limit the performance of the proposed techniques in the population of interest through the following aims:

  • Aim 1: Determine the bias and precision (repeatability) of emerging free-breathing MRI-based liver fat quantification in children with obesity and controls using current breath-held methods as a reference.
  • Aim 2: Determine the precision (repeatability and reproducibility) of US-based biomarkers of liver steatosis with a focus on the impact of body wall thickness on the precision of the biomarkers.

Enrollment

24 estimated patients

Sex

All

Ages

10 to 14 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Age: 10 - 14years old
  2. BMI: Case subjects: BMI>95th percentile for age and sex Healthy BMI volunteers: 5th ≤ BMI < 85th percentile for age and sex

Exclusion criteria

  1. Children with contraindications to MRI.
  2. Children who did not fast (verbally confirmed by children or guardian)
  3. Pregnant

Trial design

24 participants in 2 patient groups

Average or low BMI
Description:
Children with BMI under the 85th percentile for age and sex
Treatment:
Device: Ultrasound (US)
Device: Magnetic Resonance Imaging (MRI)
High BMI
Description:
Children with BMI in the 95th percentile or higher for age and sex
Treatment:
Device: Ultrasound (US)
Device: Magnetic Resonance Imaging (MRI)

Trial contacts and locations

1

Loading...

Central trial contact

Suzanne Hanson, BS; Gemma Gliori, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems